XC-8 is under clinical development by JSC Valenta Pharmaceuticals and currently in Phase III for Acute Bronchitis. According to GlobalData, Phase III drugs for Acute Bronchitis have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how XC-8’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XC-8 overview
XC-8 is under development for the treatment of dry non-productive cough associated with acute viral respiratory tract infections, acute viral upper respiratory tract infections and acute bronchitis. It is administered through oral route in the film coated tablets.
For a complete picture of XC-8’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.